Nizoral is a Small Molecule owned by Johnson & Johnson, and is involved in 4 clinical trials, which were completed.

Ketoconazole is a synthetic derivative of phenylpiperazine with broad antifungal properties. Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall.

The revenue for Nizoral is expected to reach a total of $847m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nizoral NPV Report.

Nizoral is currently owned by Johnson & Johnson. Alliance Pharma is the other company associated in development or marketing of Nizoral.

Nizoral Overview

Ketoconazole (Nizoral, Nizoral GR, Nizral, Daktarin Gold, Terzolin, Ketoderm, Fungarest, Cetonax, Nizoral A-D, Triatop, Niz, Fungoral, Ketoconazole Patriot) is an anti fungal, anti infective agent. It is formulated as gel, solution, lotion, shampoo and cream for topical application and as tablets, granules and suspension for oral route of administration and ovule for vaginal route administration. Ketoconazole is indicated for the treatment of fungal infections, skin infections, dermatophytosis, onychomycosis (tinea unguium), pityriasis simplex capillitii (dandruff), folliculitis, vulvovaginal candidiasis, histoplasmosis, coccidioidomycosis, blastomycosis, cutaneous candidiasis,athlete''s foot (tinea pedis), tinea corporis, tinea cruris (jock itch), tinea capitis, seborrhea, dermatitis. Nizoral ovule is indicated for the treatment of acute and chronic vaginal candidiasis.

Alliance Pharma Overview

Alliance Pharma (Alliance) is a specialty pharmaceutical company. It focuses on acquisition, licensing, registration, and marketing of pharmaceutical products. The company offers acquired and licensed prescription products across various therapeutic categories such as dermatology, central nervous system, women’s health, infectious disease, respiratory, immunology, gastrointestinal, nutrition, toxicology and mouth and dental disorders. It distributes products through wholesalers, retail pharmacies, hospitals and international network of distributors. The company operates in the UK, Ireland, British Virgin Islands, France, the US, and Germany. Alliance is headquartered in Chippenham, Wiltshire, UK.

The company reported revenues of (British Pounds) GBP163.2 million for the fiscal year ended December 2021 (FY2021), an increase of 25.7% over FY2020. In FY2021, the company’s operating margin was 13.2%, compared to an operating margin of 12.6% in FY2020. In FY2021, the company recorded a net margin of 4.5%, compared to a net margin of 6.2% in FY2020.

Quick View – Nizoral

Report Segments
  • Innovator (NME)
Drug Name
  • Nizoral
Administration Pathway
  • Oral
  • Topical
  • Vaginal
Therapeutic Areas
  • Dermatology
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.